{
    "ticker": "SYRS",
    "name": "Syros Pharmaceuticals, Inc.",
    "description": "Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative gene control therapies for patients with cancer and other diseases. Founded in 2012, Syros leverages its proprietary gene regulation platform to discover and develop therapies that target the underlying genetic drivers of disease. The company aims to significantly improve patient outcomes by designing drugs that precisely modulate the expression of genes involved in cancer progression. Syros is advancing a pipeline of product candidates, including SY-1425, an oral selective retinoic acid receptor alpha (RARA) modulator currently in clinical trials for the treatment of acute myeloid leukemia (AML) and other malignancies. In addition to its lead product candidate, Syros is exploring therapies for solid tumors and has collaborations with leading pharmaceutical companies to expand its reach and capabilities in the oncology landscape. With a commitment to innovation and patient care, Syros is poised to make significant contributions to the field of precision medicine and cancer therapeutics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2012",
    "website": "https://www.syros.com",
    "ceo": "Nancy Simonian",
    "social_media": {
        "twitter": "https://twitter.com/SyrosPharma",
        "linkedin": "https://www.linkedin.com/company/syros-pharmaceuticals/"
    },
    "investor_relations": "https://investors.syros.com",
    "key_executives": [
        {
            "name": "Nancy Simonian",
            "position": "CEO"
        },
        {
            "name": "David A. Mott",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "SY-1425",
                "SY-1365"
            ]
        }
    ],
    "seo": {
        "meta_title": "Syros Pharmaceuticals, Inc. | Innovating Gene Control Therapies",
        "meta_description": "Explore Syros Pharmaceuticals, Inc., a leader in gene control therapies for cancer treatment. Learn about our innovative pipeline and commitment to advancing precision medicine.",
        "keywords": [
            "Syros Pharmaceuticals",
            "Oncology",
            "Gene Control",
            "Cancer Therapeutics",
            "Precision Medicine"
        ]
    },
    "faq": [
        {
            "question": "What does Syros Pharmaceuticals focus on?",
            "answer": "Syros Pharmaceuticals focuses on developing gene control therapies for cancer and other diseases."
        },
        {
            "question": "Who is the CEO of Syros Pharmaceuticals?",
            "answer": "Nancy Simonian is the CEO of Syros Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Syros headquartered?",
            "answer": "Syros is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are the main products of Syros?",
            "answer": "Syros's main products include SY-1425 and SY-1365, which are in development for cancer treatment."
        },
        {
            "question": "When was Syros Pharmaceuticals founded?",
            "answer": "Syros Pharmaceuticals was founded in 2012."
        }
    ],
    "competitors": [
        "BMY",
        "EXEL",
        "CLVS",
        "NVS"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}